Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ) (BIOVF) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
biovf · stock forecast · 1 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 1 Wall Street analysts in the past 3 months
Hold
1 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $48.00
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $47.91 | ↓ 0.19% |
1-day model range: $47.62–$48.2. Peak: $48.2 (-0.19%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $77 | +60.0% |
| 2028 | $107 | +122.4% |
| 2029 | $134 | +178.8% |
| 2030 | $156 | +224.7% |
| 2031 | — | +259.5% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · BIOVF · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2021-02-24 | Barclays | Downgrade ↓ | Overweight→Equal Weight |
Wall Street analysts have recently issued updated ratings on Swedish Orphan Biovitrum AB (publ) (BIOVF) stock. Of the recent 1 rating actions, 0 were upgrades and 1 were downgrades. 1 analysts currently cover BIOVF.
Analyst Recommendation Trends
BIOVF analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$32.1B
↓ 21.1% YoY
Revenue Next Year
$36.7B
↑ 14.2% YoY
EPS This Year
$18.21
EPS Next Year
$23.43
↑ 28.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast BIOVF EPS of $18.21 for the current fiscal year, based on estimates from 1 analysts. The BIOVF revenue forecast is $32.1B for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BIOVF stock forecast is supported by two independent data sources: analyst consensus ratings from 1 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BIOVF price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The BIOVF short-term stock prediction for tomorrow is $47.91 (-0.19%). The BIOVF stock price prediction for 2027 estimates an average of $77. The BIOVF stock prediction for 2030 projects a range of $148–$163.
Swedish Orphan Biovitrum AB (publ) trades on OTC under the ticker BIOVF. The BIOVF stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 0% of covering analysts.
Frequently asked questions
BIOVF forecast · 8 questionsAccording to 1 Wall Street analysts, the average 12-month BIOVF price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $48.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.